Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects

International Journal of Obesity

Volumn 27, Issue 11, 2003, Pages 1359-1364

  Velasquez Mieyer, P A ^a,c   Cowan, P A ^a   Umpierrez, G E ^a   Lustig, R H ^b   Cashion, A K ^a   Burghen, G A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LE BONHEUR CHILDREN S HOSPITAL   (United States)

Author keywords

cell activity; GLP 1; Insulin; Racial

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INSULIN;

ADULT; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; FEMALE; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NEGRO; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RACE DIFFERENCE;

ADULT; AFRICAN AMERICANS; ANTHROPOMETRY; BODY COMPOSITION; BODY MASS INDEX; ENERGY INTAKE; FASTING; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; OBESITY; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0242576096     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802415     Document Type: Article

References (39)

1. Campfield LA, Smith FJ. The pathogenesis of obesity. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13: 13-30.
2. Le Stunff C, Bougneres P. Early changes in postprandial insulin secretion, not in insulin sensitivity, characterize juvenile obesity. Diabetes 1994; 43: 696-702.
3. Odeleye OE, de Courten M, Pettitt DJ, Ravussin E. Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children. Diabetes 1997; 46: 1341-1345.
4. Zannolli R, Rebeggiani A, Chiarelli F, Morgese G. Hyperinsulinism as a marker in obese children. Am J Dis Child 1993; 147: 837-841.
5. Dowling HJ, Pi-Sunyer FX. Race-dependent health risks of upper body obesity. Diabetes 1993; 42: 537-543.
6. Haffner SM, D'Agostino R, Saad MF, Rewers M, Mykkanen L, Selby J, Howard G, Savage PJ, Hamman RF, Wagenknecht LE, Bergman RN. Increased insulin resistance and insulin secretion in non-diabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes 1996; 45: 742-748.
7. Jiang X, Srinivasan SR, Radhakrishnamurthy B, Dalferes ER, Berenson GS. Racial (black-white) differences in insulin secretion and clearance in adolescents: the Bogalusa heart study. Pediatrics 1996; 97: 357-760.
8. Arslanian S, Suprasongsin C. Differences in the in vivo insulin secretion and sensitivity of healthy black versus white adolescents. J Pediatr 1996; 129: 440-443.
9. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969; 123: 261-266.
10. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994; 107: 1848-1855.
11. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA. Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol 1983; 244: E517-E527.
12. Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol 2000; 143: 717-725.
13. Brandt A, Katschinski M, Arnold R, Polonsky KS, Goke B, Byrne MM. GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol Endocrinol Metab 2001; 281: E242-E247.
14. Holz GGt, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361: 362-365.
15. Leech CA, Holz GG, Habener JF. Signal transduction of PACAP and GLP-1 in pancreatic beta cells. Ann NY Acad Sci 1996; 805: 81-92; discussion 92-93.
16. 2+, signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). J Biol Chem 1999; 274: 14147-14156.
17. Nie Y, Nakashima M, Brubaker PL, Li QL, Perfetti R, Jansen E, Zambre Y, Pipeleers D, Friedman TC. Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J Clin Invest 2000; 105: 955-965.
18. Reaven GM, Brand RJ, Chen YD, Mathur AK, Goldfine I. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes 1993; 42: 1324-1332.
19. ADA. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
20. Kadish AH, Little RH, Sternberg JC. A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin Chem 1968; 14: 116-119.
21. Guven S, El-Bershawi A, Sonnenberg GE, Wilson CR, Hoffmann RG, Krakower GR, Kissebah AH. Plasma leptin and insulin levels in weight-reduced obese women with normal body mass index: relationships with body composition and insulin. Diabetes 1999; 48: 347-352.
22. Jensen MD, Hensrud D, O'Brien PC, Nielsen S. Collection and interpretation of plasma leptin concentration data in humans. Obes Res 1999; 7: 241-245.
23. Toft I, Bonaa KH, Lindal S, Jenssen T. Insulin kinetics, insulin action, and muscle morphology in lean or slightly overweight persons with impaired glucose tolerance. Metabolism 1998; 47: 848-854.
24. Sluiter WJ, Erkelens DW, Terpstra P, Reitsma WD, Doorenbos H. Glucose tolerance and insulin release, a mathematical approach. II. Approximation of the peripheral insulin resistance after oral glucose loading. Diabetes 1976; 25: 245-249.
25. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
26. Uwaifo GI, Nguyen TT, Keil MF, Russell DL, Nicholson JC, Bonat SH, McDuffie JR, Yanovski JA. Differences in insulin secretion and sensitivity of Caucasian and African American prepubertal children. J Pediatr 2002; 140: 673-680.
27. Tallarida RJ, Murray RB. Manual of pharmacologic calculations with computer programs. Springer-Verlag: New York; 1986. pp 77-81.
28. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991; 337: 382-386.
29. Svec F, Nastasi K, Hilton C, Bao W, Srinivasan SR, Berenson GS. Black-white contrasts in insulin levels during pubertal development. The Bogalusa Heart Study. Diabetes 1992; 41: 313-317.
30. Orskov C, Andreasen J, Holst JJ. All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab 1992; 74: 379-384.
31. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996; 271: E458-E464.
32. Ruiz-Grande C, Alarcon C, Alcantara A, Castilla C, Lopez Novoa JM, Villanueva-Penacarrillo ML, Valverde I. Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 1993; 25: 612-616.
33. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.
34. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131.
35. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913.
36. Freidenberg GR, Klein HH, Cordera R, Olefsky JM. Insulin receptor kinase activity in rat liver. Regulation by fasting and high carbohydrate feeding. J Biol Chem 1985; 260: 12444-12453.
37. Ramsay TG. Fat cells. Endocrinol Metab Clin North Am 1996; 25: 847-870.
38. Widmann C, Dolci W, Thorens B. Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. Mol Endocrinol 1996; 10: 62-75.
39. Wettergren A, Wojdemann M, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 1998; 19: 877-882.